ConductScience.org, home

Paper8940976

A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children.

Marti H and 6 others. Am J Trop Med Hyg, 1996. Cited by 207 papers, by iCite.

Cite this record

ConductScience Library. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Papers, record 8940976. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8940976

Download JSON
Disease
trichuriasis6 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children.
PubMed
Journal
Am J Trop Med Hyg
PubMed
Year
1996
PubMed
Publication types
Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
207
iCite
Relative citation ratio, by iCite
8.22
iCite
Revised in PubMed
2019-05-16
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Marti HH
2Haji HJH J
3Savioli LL
4Chwaya HMH M
5Mgeni AFA F
6Ameir JSJ S
7Hatz CC

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AlbendazoleMajor topic
AnthelminticsMajor topic
HelminthiasisMajor topic
IvermectinMajor topic
StrongyloidiasisMajor topic
Adolescent
Adult
Ancylostomatoidea
Animals
Ascaris lumbricoides
Child
Female
Follow-Up Studies
Humans
Male
Strongyloides stercoralis
Tanzania
Trichuris

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT07045493Assessing the Safety and Efficacy of a Combination Therapy for STH in PSAC in BangladeshResults

Source ClinicalTrials.gov

Download CSV of trials

Cited by87

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 207 citations.

PMIDTitleJournalYearIn PapersSource
42553508Duodenal Strongyloidiasis Mimicking Inflammatory Bowel Disease: A Case Report of a 52-Year-Old Immunocompetent Woman.Clin Med Insights Case Rep2026https://conductscience.org/library/papers/42553508PubMed
42365991Investigation of Donor-Transmitted Strongyloides stercoralis Infections in Solid Organ Transplant Recipients, United States, 2012-2024.Emerg Infect Dis2026https://conductscience.org/library/papers/42365991PubMed
40257544Antitumor potential of ivermectin against T-cell lymphoma-bearing hosts.Med Oncol2025https://conductscience.org/library/papers/40257544PubMed
39719576Strongyloidiasis mimics duodenal lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome: a case report.J Med Case Rep2024https://conductscience.org/library/papers/39719576PubMed
38369483Effectiveness of ivermectin mass drug administration in the control of soil-transmitted helminth infections in endemic populations: a systematic review and meta-analysis.Infect Dis Poverty2024https://conductscience.org/library/papers/38369483PubMed
38357395
Effectiveness of one and two doses of ivermectin mass drug administration in reducing the prevalence and intensity of soil-transmitted helminth (STH) infections in Western Province, Solomon Islands: a cluster-randomised, before-after analysis.
Lancet Reg Health West Pac2024https://conductscience.org/library/papers/38357395PubMed
37947530Who Let the Dogs Out? Unmasking the Neglected: A Semi-Systematic Review on the Enduring Impact of Toxocariasis, a Prevalent Zoonotic Infection.Int J Environ Res Public Health2023https://conductscience.org/library/papers/37947530PubMed
37068106A comparative 'omics' approach for prediction of candidate Strongyloides stercoralis diagnostic coproantigens.PLoS Negl Trop Dis2023https://conductscience.org/library/papers/37068106PubMed
36540062
An adaptive phase II/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the treatment of Trichuris trichiura and other STH infections. ALIVE trial protocol.
Gates Open Res2022https://conductscience.org/library/papers/36540062PubMed
35848982Herbal anthelmintic agents: a narrative review.J Tradit Chin Med2022https://conductscience.org/library/papers/35848982PubMed
35615701Polymicrobial bacteremia and Strongyloides hyperinfection syndrome: Vigilance in patients on corticosteroids.IDCases2022https://conductscience.org/library/papers/35615701PubMed
35143567Impact of ivermectin mass drug administration on burden of soil-transmitted helminths in onchocerciasis control and elimination programs, Yeki district, southwest Ethiopia.PLoS One2022https://conductscience.org/library/papers/35143567PubMed
34632308Efficacy and safety of moxidectin and albendazole compared to ivermectin and albendazole co-administration in adolescents infected with Trichuris trichiura: a randomized controlled trial protocol.Gates Open Res2021https://conductscience.org/library/papers/34632308PubMed
34576800Strongyloidiasis in Children Outside the Tropics: Do We Need to Increase Awareness?Microorganisms2021https://conductscience.org/library/papers/34576800PubMed
34430453Current Use of Ivermectin in Dermatology, Tropical Medicine, and COVID-19: An Update on Pharmacology, Uses, Proven and Varied Proposed Mechanistic Action.Indian Dermatol Online J2021https://conductscience.org/library/papers/34430453PubMed
34323283Broadening the range of use cases for ivermectin - a review of the evidence.Trans R Soc Trop Med Hyg2022https://conductscience.org/library/papers/34323283PubMed
32669892Human strongyloidiasis: identifying knowledge gaps, with emphasis on environmental control.Res Rep Trop Med2014https://conductscience.org/library/papers/32669892PubMed
32474842Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug.Cancer Chemother Pharmacol2020https://conductscience.org/library/papers/32474842PubMed
32418379Effectiveness of Mass Drug Administration on Neglected Tropical Diseases in Schoolchildren in Zanzibar, Tanzania.Korean J Parasitol2020https://conductscience.org/library/papers/32418379PubMed
32289194Anthelmintic drugs for treating ascariasis.Cochrane Database Syst Rev2020https://conductscience.org/library/papers/32289194PubMed

See all 87 cited byDownload CSV of cited by

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
ALBENDAZOLECHEMBL1483Results1https://conductscience.org/library/drugs/CHEMBL1483ChEMBL
IVERMECTINCHEMBL6067487Results1https://conductscience.org/library/drugs/CHEMBL6067487ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8940976

GET https://conductscience.org/api/papers/v1/8940976/cited_by?page=2